Crinetics Pharmaceuticals gains FDA approval for PALSONIFY, targeting key unmet needs in Acromegaly. Click here to read my ...

The U.S. Food and Drug Administration approved Crinetics Pharmaceuticals' drug to treat a rare hormonal disorder on Thursday, ...

The regulatory greenlight was backed by two Phase III trials that showed normalized growth hormone levels in patients with ...

The Food and Drug Administration (FDA) has approved Palsonify ™ (paltusotine) for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an ...

Paltusotine (Palsonify; Crinetics), a novel nonpeptide somatostatin receptor type 2 nonpeptide (SST2) agonist, was approved by the FDA for the treatment of acromegaly in adults who had an inadequate ...

Obesity is a growing crisis in India, significantly increasing the risk of at least 12 cancers. Fat cells actively promote ...

Start fueling your body with the nutrients it craves to grow stronger and recover faster. Milk is more than a childhood drink—it’s a powerhouse for performance and resilience. Add it to your daily ...

PALSONIFY™ (paltusotine) INDICATION: PALSONIFY is a somatostatin receptor agonist indicated for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom ...

Crinetics’ PALSONIFY wins FDA approval as a new oral treatment for acromegaly, offering rapid, effective symptom control.

Novel nonpeptide SST2 agonist PALSONIFY advances the treatment paradigm as the first once-daily, oral therapy approved by the FDA to treat acromegaly Approval based on data from two pivotal Phase 3 ...

Researchers reviewed current evidence on the chaya plant (Cnidoscolus chayamansa), highlighting its nutritional profile, ...